- Home
- FET vs CLLS Comparison
FET vs CLLS Comparison
Compare FET & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FET
- CLLS
- Stock Information
- Founded
- FET 2005
- CLLS 1999
- Country
- FET United States
- CLLS France
- Employees
- FET N/A
- CLLS N/A
- Industry
- FET Metal Fabrications
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- FET Industrials
- CLLS Health Care
- Exchange
- FET Nasdaq
- CLLS Nasdaq
- Market Cap
- FET 309.5M
- CLLS 299.0M
- IPO Year
- FET 2012
- CLLS 2007
- Fundamental
- Price
- FET $26.78
- CLLS $3.45
- Analyst Decision
- FET
- CLLS Buy
- Analyst Count
- FET 0
- CLLS 1
- Target Price
- FET N/A
- CLLS $8.00
- AVG Volume (30 Days)
- FET 113.7K
- CLLS 179.7K
- Earning Date
- FET 10-30-2025
- CLLS 11-07-2025
- Dividend Yield
- FET N/A
- CLLS N/A
- EPS Growth
- FET N/A
- CLLS N/A
- EPS
- FET N/A
- CLLS N/A
- Revenue
- FET $790,292,000.00
- CLLS $63,438,000.00
- Revenue This Year
- FET N/A
- CLLS N/A
- Revenue Next Year
- FET $0.41
- CLLS $66.76
- P/E Ratio
- FET N/A
- CLLS N/A
- Revenue Growth
- FET N/A
- CLLS 223.09
- 52 Week Low
- FET $12.78
- CLLS $1.10
- 52 Week High
- FET $33.06
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- FET 43.33
- CLLS 46.16
- Support Level
- FET $30.40
- CLLS $3.43
- Resistance Level
- FET $33.06
- CLLS $3.79
- Average True Range (ATR)
- FET 1.44
- CLLS 0.32
- MACD
- FET 0.05
- CLLS -0.09
- Stochastic Oscillator
- FET 11.05
- CLLS 4.25
About FET Forum Energy Technologies Inc.
Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in two reporting segments, namely Drilling and Completions and Artificial Lift and Downhole. Revenue largely comes from Artificial Lift and Downhole segment.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.